Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Friedrichshafen, Germany Clinical Trials

A listing of Friedrichshafen, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (16) clinical trials

Apixaban for Treatment of Embolic Stroke of Undetermined Source

Based on the previous data, ATTICUS is designed as multicentre, national, parallel group, active controlled, phase III randomized (2x2 factorial), clinical trial to demonstrate the superiority of apixaban against the current standard of treatment (acetylsalicylic acid) for the longterm treatment after ESUS. ATTICUS will follow a dynamic treatment protocol implementing ...

Phase

0.0 miles

Learn More »

A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy

Secondary objectives are assessment of safety and feasibility of the sequential cross-over treatment approach for advanced treatment lines in PDAC. 204 patients will be randomized into the treatments arms. Cross-over will take place after progress during second line therapy.

Phase

0.0 miles

Learn More »

Post-Market Clinical Follow Up of Rotarex S Catheter

A prospective, multi-center, non-randomized, multiple cohorts, observational, post market clinical follow-up study of the RotarexS Catheter to evaluate the safety, technical performance and medical efficacy of the RotarexS Catheter as a stand-alone and adjunctive therapy for the treatment of acute, subacute and chronic occlusions and sub-occlusions of arteries outside the ...

Phase N/A

0.0 miles

Learn More »

A Study to Evaluate ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis

The study evaluates four dose levels of ABY-035, in comparison to placebo, in subjects with moderate to severe plaque psoriasis. The study consists of a four week screening period, three treatment periods and a four-week follow-up period. The treatment periods are: Randomized treatment; four dose levels and placebo. Biweekly (Q2W) ...

Phase

1.9 miles

Learn More »

Phase 2b Study to Evaluate the Efficacy and Safety of GBR 830 in Adults With Moderate to Severe Atopic Dermatitis

Phase 2b, randomized, double-blinded, placebo-controlled dose range finding study to evaluate the efficacy, safety and tolerability of GBR 830 in adults with moderate to severe atopic dermatitis.

Phase

1.9 miles

Learn More »

Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome

Around 40% of moderate to severe psoriasis patients are affected by concomitant metabolic syndrome, making it one of the clinically most relevant comorbidities. Psoriasis as well as the metabolic syndrome are both characterized by a state of low-grade systemic inflammation (e.g. in the skin, joints, adipose tissue, liver or vascular ...

Phase

1.9 miles

Learn More »

Adjuvant Aspirin Treatment for Colon Cancer Patients

Colorectal cancer is the third most common malignancy for both women and men and is responsible for almost 10% of all cancer death. Despite complete removal of the tumor and use of adjuvant chemotherapy, up to 25% of patients with stage II colon cancer and up to 50% of patients ...

Phase

1.9 miles

Learn More »

Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy

This randomized trial examines the effectiveness of chemoradiotherapy compared to chemotherapy alone after induction chemotherapy with 3 cycles of gemcitabine or 6 cycles of FOLFIRINOX in patients with locally advanced, non resectable and non-metastatic pancreatic cancer. Chemotherapeutic agent in chemoradiotherapy is gemcitabine administered in 5 cycles, the agent and its ...

Phase

1.9 miles

Learn More »

Therapy Optimisation for the Treatment of Hairy Cell Leukemia

Evaluation of remission status will take place 4 months after treatment. In addition, it will be tested whether patients with non-optimal response will have a benefit from a second cycle of cladribine. Non-optimal response is: patients with detectable residual disease; achievement of partial remission or detectable residual infiltration in the ...

Phase

1.9 miles

Learn More »

A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis

The purpose of this study is to demonstrate that Super-Responders (SRe; defined as psoriasis participants who receive on-label guselkumab treatment until week 20 and respond with a Psoriasis Area and Severity Index score (PASI) = 0 at weeks 20 and 28) maintain control of disease until week 68 with prolonged ...

Phase

1.9 miles

Learn More »